ContraVir Pharmaceuticals (CTRV) Getting Somewhat Favorable Press Coverage, Analysis Shows

News coverage about ContraVir Pharmaceuticals (NASDAQ:CTRV) has been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ContraVir Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.2723592194263 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the media stories that may have impacted Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

Several equities analysts recently commented on the stock. Maxim Group lowered shares of ContraVir Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 13th. ValuEngine raised shares of ContraVir Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.

Shares of ContraVir Pharmaceuticals stock traded down $0.01 during mid-day trading on Friday, reaching $0.24. 782,886 shares of the company traded hands, compared to its average volume of 1,382,224. ContraVir Pharmaceuticals has a 1 year low of $0.20 and a 1 year high of $1.96. The firm has a market capitalization of $19.49, a price-to-earnings ratio of -0.49 and a beta of 1.88.

COPYRIGHT VIOLATION WARNING: “ContraVir Pharmaceuticals (CTRV) Getting Somewhat Favorable Press Coverage, Analysis Shows” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/3300312/contravir-pharmaceuticals-ctrv-getting-somewhat-favorable-press-coverage-analysis-shows.html.

ContraVir Pharmaceuticals Company Profile

ContraVir Pharmaceuticals, Inc is focused on curing hepatitis B through the combination of direct and indirect acting antiviral compounds. Its two assets tenofovir exalidex, or TXL, and CRV431 have complementary mechanisms of action and have shown potential synergy against hepatitis B virus (HBV). TXL is designed to deliver high intrahepatic concentrations of TFV while minimizing off target effects caused by high levels of circulating TFV, and has completed a Phase IIa trial.

Insider Buying and Selling by Quarter for ContraVir Pharmaceuticals (NASDAQ:CTRV)

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Hornbeck Offshore Services  Expected to Announce Quarterly Sales of $50.37 Million
Hornbeck Offshore Services Expected to Announce Quarterly Sales of $50.37 Million
$1.94 Billion in Sales Expected for The Hershey Company  This Quarter
$1.94 Billion in Sales Expected for The Hershey Company This Quarter
DXC Technology  Given Media Impact Score of 0.05
DXC Technology Given Media Impact Score of 0.05
Yum! Brands  Earning Somewhat Positive Media Coverage, Report Shows
Yum! Brands Earning Somewhat Positive Media Coverage, Report Shows
FIS  Receives News Sentiment Rating of 0.15
FIS Receives News Sentiment Rating of 0.15
Nokia  Earns Media Sentiment Rating of 0.21
Nokia Earns Media Sentiment Rating of 0.21


© 2006-2018 Ticker Report. Google+.